Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate ...

Q1 2025 Earnings Call Transcript May 7, 2025 ACADIA Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.11, ...

Top Minnesota basketball seniors Nolan Groves and Chase Thompson were only a couple of months removed from battling on ...